SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

8306	Companies
115305	Keywords
55588	Articles
62608	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 09/11/2024 at 07:00, 2 months 11 days ago

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
Dupixent achieves significant improvements in disease remission and symptoms in bullous pemphigoid study. Study met primary and key secondary endpoints with beneficial steroid-sparing effect

Dupixent Bullous Pemphigoid Disease Remission Symptoms Steroid-sparing Effect
BRIEF

published on 08/09/2024 at 21:16, 3 months 12 days ago

Sanofi publie les chiffres de son capital et de ses droits de vote en juillet 2024

Autorité Des Marchés Financiers Droits De Vote Capital Social Juillet 2024 Actions Sanofi
BRIEF

published on 08/09/2024 at 21:16, 3 months 12 days ago

Sanofi publishes its capital and voting rights figures for July 2024

Share Capital Voting Rights Financial Markets Authority July 2024 Sanofi Actions
PRESS RELEASE

published on 08/09/2024 at 21:11, 3 months 12 days ago

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2024
Publication des informations relatives au nombre total de droits de vote et d’actions de Sanofi selon l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’AMF

Droits De Vote Actions AMF Informations Financières Sanofi
PRESS RELEASE

published on 08/09/2024 at 21:11, 3 months 12 days ago

Sanofi: Information concerning the total number of voting rights and shares - July 2024
Sanofi discloses total voting rights and shares as per French Commercial Code and AMF Regulations for July 31, 2024

French Commercial Code Total Voting Rights AMF Regulations Sanofi July 31 2024
BRIEF

published on 08/08/2024 at 07:05, 3 months 14 days ago

Sarclisa améliore la survie sans progression pour les patients atteints de myélome multiple éligibles à une transplantation

Étude Clinique Sanofi Myélome Multiple Sarclisa Survie Sans Progression
BRIEF

published on 08/08/2024 at 07:05, 3 months 14 days ago

Sarclisa Improves Progression-Free Survival for Multiple Myeloma Patients Eligible for Transplant

Clinical Study Sanofi Multiple Myeloma Sarclisa Progression-free Survival
PRESS RELEASE

published on 08/08/2024 at 07:00, 3 months 14 days ago

Communiqué : Le traitement d’induction par Sarclisa a démontré une amélioration significative de la survie sans progression chez les patients atteints d’un myélome multiple nouvellement diagnostiqué et éligibles à une transplantation
Le traitement d’induction par Sarclisa montre une amélioration significative de la survie sans progression chez les patients atteints de myélome multiple nouvellement diagnostiqués et éligibles à une transplantation

Myélome Multiple Sarclisa Survie Sans Progression Traitement D'induction GMMG-HD7
PRESS RELEASE

published on 08/08/2024 at 07:00, 3 months 14 days ago

Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
New data shows Sarclisa induction therapy improves progression-free survival in transplant-eligible newly diagnosed multiple myeloma patients. GMMG-HD7 study results are promising for Sarclisa as part of frontline treatment

Multiple Myeloma Sarclisa Progression-free Survival GMMG-HD7 Study Frontline Treatment
BRIEF

published on 07/22/2024 at 22:10, 3 months 30 days ago

Sanofi Announces Total Number of Voting Rights and Shares for June 2024

Voting Rights French Commercial Code Financial Regulations Sanofi Shares 2024

Accesswire

Published on 11/22/2024 at 15:55, 11 minutes ago

Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Published on 11/22/2024 at 15:15, 51 minutes ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Published on 11/22/2024 at 14:45, 1 hour 21 minutes ago

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Published on 11/22/2024 at 14:30, 1 hour 36 minutes ago

Allied Universal Named Presenting Sponsor of 2024 Lott IMPACT Trophy Recognizing College Football's Defensive Best
Published on 11/22/2024 at 14:20, 1 hour 46 minutes ago

Plaintree Systems Inc. Announces Second Quarter Fiscal 2025 Results

View all ACCESSWIRE

EQS Group

Published on 11/22/2024 at 15:27, 39 minutes ago

EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again
Published on 11/22/2024 at 14:46, 1 hour 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/22/2024 at 14:45, 1 hour 20 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/22/2024 at 14:44, 1 hour 21 minutes ago

Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc
Published on 11/22/2024 at 14:43, 1 hour 22 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Distribution Services plc

Les Echos

Published on 11/22/2024 at 14:35, 1 hour 31 minutes ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 1 hour 31 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 1 day 9 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 9 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 9 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille

View all LES ECHOS COMFI WIRE